+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Azacitidine"

From
Blood Cancer Drugs Market Report 2025 - Product Thumbnail Image

Blood Cancer Drugs Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Myelodysplastic Syndrome (MDS) Drugs Market Report 2025 - Product Thumbnail Image

Myelodysplastic Syndrome (MDS) Drugs Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
Myelodysplastic Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 250 Pages
  • Global
From
Blastic Plasmacytoid Dendritic cell neoplasm - Pipeline Insight, 2024 - Product Thumbnail Image

Blastic Plasmacytoid Dendritic cell neoplasm - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
From
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Azacitidine is a drug used in the treatment of certain types of cancer, such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). It is a pyrimidine analog, which works by inhibiting the growth of cancer cells and inducing apoptosis. Azacitidine is administered intravenously or subcutaneously, and is often used in combination with other drugs. Azacitidine is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2014. It is used to treat patients who have not responded to other treatments, and is considered a breakthrough therapy for MDS. The azacitidine market is highly competitive, with several major players in the field. These include Celgene Corporation, Teva Pharmaceuticals, Pfizer, and Novartis. Other companies involved in the market include Merck, Johnson & Johnson, and Bristol-Myers Squibb. Show Less Read more